Drugs › Vascular endothelial growth factor receptor 2 antagonist
Brand name · Ramucirumab
Cyramza: adverse event reports filed with FDA
3,967 reports list it as a suspect or interacting product, 2014–2026. Class: Vascular endothelial growth factor receptor 2 antagonist.
- 3,967
- reports as suspect product
- 0% of all reports · about 328 a year
- 195
- reports, 12 months to June 2026
- 226 in the 12 months before
- 91.9%
- marked serious by the reporter
- 94% across the class
- 28.8%
- record death among outcomes, as reported
- 1,143 reports · not verified by FDA
3,967 adverse event reports received by FDA list the brand name Cyramza (ramucirumab) as a suspect or interacting product, from June 2014 to June 2026. A further 171 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 195 reports listed it, down 14% from 226 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 328 reports a year and 0% of the 20,646,523 reports in the database, and 70.1% of the reports for the vascular endothelial growth factor receptor 2 antagonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
The MedDRA terms listed most often are malignant neoplasm progression (13.4%), death (11.1%) and interstitial lung disease (6.2%). A report can list several reactions, so shares add to more than 100%; 450 different terms appear across these reports. Malignant neoplasm progression is recorded in 13.4% of these reports, about the same share as in the median vascular endothelial growth factor receptor 2 antagonist drug (13.6%).
91.9% of the reports are marked serious by the reporter (94% across the class); 28.8% record death among the outcomes and 36.9% record hospitalisation, as reported. 65.5% of the reports came from consumers, and the largest patient age group is 65 to 74 (26.6%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Cyramza reports recording the termmedian drug in vascular endothelial growth factor receptor 2 antagonist
- Malignant neoplasm progression13.4%532
- Deaththe patient died; cause not stated by this term11.1%440
- Interstitial lung diseasescarring or inflammation of lung tissue6.2%245
- Febrile neutropeniafever with low white blood cells3.9%154
- Hypertensionhigh blood pressure3%118
- Pneumonialung infection2.8%110
- Decreased appetitereduced appetite2.5%101
- Diarrhoealoose or frequent stools2.5%99
- Ascitesfluid in the abdomen2.4%94
- Off label useused for a purpose or in a way not on the label2.4%94
- Neutropenialow neutrophils, a type of white blood cell2.3%90
- Proteinuriaprotein in the urine2.1%83
- Pyrexiafever2.1%83
- Nauseafeeling sick2.1%82
- Peritonitis2%80
- Platelet count decreasedlow platelet count1.8%72
- Malaisegeneral feeling of being unwell1.7%69
- Abdominal painstomach or belly pain1.7%68
- Fatiguetiredness1.7%68
- Tumour haemorrhage1.7%68
- Neuropathy peripheralnerve damage in hands or feet1.7%66
- Pneumonitis1.6%64
- Vomitingbeing sick1.6%64
- Dyspnoeashortness of breath1.5%61
- Anaemialow red blood cells1.5%58
- White blood cell count decreasedlow white cell count1.4%56
- Nephrotic syndrome1.4%55
- Gastrointestinal perforationa hole in the stomach or bowel1.4%54
- Epistaxisnosebleed1.3%53
Top 30 of 450 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 2 drugs in the vascular endothelial growth factor receptor 2 antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 5,658 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 21.2% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Gastric cancer | 970 | 24.5% |
| Lung neoplasm malignant | 283 | 7.1% |
| Non-small cell lung cancer | 268 | 6.8% |
| Colon cancer | 187 | 4.7% |
| Gastric cancer stage iv | 142 | 3.6% |
| Adenocarcinoma gastric | 115 | 2.9% |
The indication field is filled in by the reporter and is often blank; shares are of all 3,967 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Cyramza reports |
|---|---|---|
| Paclitaxel | 1,091 | 27.5% |
| Docetaxel | 594 | 15% |
| Fluorouracil | 230 | 5.8% |
| Irinotecan | 222 | 5.6% |
| Abraxane | 152 | 3.8% |
| Taxol | 129 | 3.3% |
| Irinotecan hydrochloride | 83 | 2.1% |
| Polaramine | 81 | 2% |
| Taxotere | 80 | 2% |
| Levoleucovorin calcium | 78 | 2% |
Other products listed in reports where Cyramza is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Cyramza | Vascular endothelial growth factor receptor 2 antagonist | All reports |
|---|---|---|---|
| Reports as suspect product | 3,967 | 5,658 | 20,646,523 |
| Share of that pool | — | 70.1% | 0% |
| Reports, latest 12 months | 195 | — | 1,332,454 |
| Marked serious | 91.9% | 94% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 288 | 270 | 91 |
| Hospitalisation recorded, per 1,000 reports | 369 | 387 | 213 |
| Consumer-filed share | 65.5% | 50.3% | 45.8% |
| Top term, share of reports | Malignant neoplasm progression 13.4% | median 13.6% | 0.5% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the vascular endothelial growth factor receptor 2 antagonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Ramucirumab | generic | 1,691 | 136 | 99% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Cyramza reports
How many adverse event reports has FDA received for Cyramza?
3,967 reports list Cyramza as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 195 of them arrived in the latest 12 months. Another 171 list it only as a concomitant medication.
What reactions are recorded in Cyramza reports?
malignant neoplasm progression (13.4%), death (11.1%), interstitial lung disease (6.2%), febrile neutropenia (3.9%) and neutrophil count decreased (3%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Cyramza was responsible.
How serious are the reports?
91.9% are marked serious by the reporter. Among the outcomes recorded, 28.8% of reports include death and 36.9% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (65.5%), physician (21.3%) and pharmacist (7.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Cyramza rising?
195 reports in the 12 months to June 2026, down 14% from 226 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Cyramza was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Cyramza?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Cyramza as a suspect or interacting product; reports listing it only as a concomitant medication (171) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.